SCHEMBL7059928

SCHEMBL7059928

CNCCOc1cccc(Cl)c1

nearest known ligand 0.67

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 2/20 0.67
DRD2 P14416 1/20 0.64
DRD4 P21917 1/20 0.64
HTR1B P28222 2/20 0.61
HTR1D P28221 1/20 0.61
LMNA P02545 2/20 0.54
SMN1; SMN2 Q16637 2/20 0.54
MAPK1 P28482 1/20 0.54
HTT P42858 1/20 0.54
KCNH2 Q12809 1/20 0.54
KDM4E B2RXH2 5/20 0.53
ALDH1A1 P00352 2/20 0.53
SLC6A4 P31645 1/20 0.52
TAAR1 Q96RJ0 1/20 0.51
CHRNB2 P17787 1/20 0.51
CHRNA4 P43681 1/20 0.51
MEN1 O00255 1/20 0.51
NSD2 O96028 1/20 0.49
L3MBTL1 Q9Y468 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6846928 0.95 KMT2A (0.69) KMT2ADRD2DRD4HTR1BHTR1D
SCHEMBL5715788 0.90 KMT2A (0.63) KMT2ADRD2DRD4HTR1BLMNA
SCHEMBL9808215 0.82 LMNA (0.67) KMT2ADRD2DRD4LMNASMN1; SMN2
SCHEMBL11455347 0.82 DRD2 (0.64) KMT2ADRD2DRD4LMNASMN1; SMN2
SCHEMBL10922507 0.81 KMT2A (0.61) KMT2ADRD2DRD4HTR1BLMNA
SCHEMBL10922023 0.81 MAPT (0.55) KMT2ADRD2DRD4HTR1BHTR1D
Dimethylamine SCHEMBL3445328 0.81 KMT2A (0.74) KMT2ADRD2DRD4LMNASMN1; SMN2
SCHEMBL8088241 0.80 HTR1B (0.63) KMT2ADRD2DRD4HTR1BHTR1D
SCHEMBL6651953 0.80 MTNR1A (0.64) HTR1BHTR1DLMNASMN1; SMN2MAPK1
SCHEMBL15829982 0.80 DRD2 (0.66) KMT2ADRD2DRD4HTR1BHTR1D

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1995241-A1 Inhibitors of ion channels ICAgen, Incorporated (US) 2008-11-26 EP disclosed
US-20030181446-A1 Novel N-acylated heterocycles RECORDATI S.A. 2003-09-25 US disclosed
US-20030162777-A1 Novel N-acylated heterocycles RECORDATI S.A. 2003-08-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030162777-A1 Novel N-acylated heterocycles HTR1A, HTR1D, HTR1E KMT2A 2287/4885DRD2 163/4885DRD4 494/4885
US-20030181446-A1 Novel N-acylated heterocycles HTR1A, HTR1E, HTR2C KMT2A 3319/4885DRD2 85/4885DRD4 157/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.